Pitch Deck for Business Development

SANA-01 ADC:
Built to bind better.

Better binding. Stronger response. More patients helped.

Since 2010, checkpoint inhibitors targeting PD-1 have grown into a $74B market.

Scientists have been attacking cancer for decades, yet current treatments help only 1 in 5 patients.

In the U.S. alone, that’s 18.6 million cancer patients waiting for effective treatment. That’s a massive unmet need.

20%

Durable response to checkpoint inhibitors

(largely melanoma)

80%
Clinical unmet need

No response (epithelial solid tumors such as lung, breast, colon, ovarian and pancreatic cancers.)

Pharma has been screening targets to find the right one.

% of patients expressing validated targets
TROP2
EGFR
c-MET
MUC1

MUC1 is the target to go after to help 80% of the patients because it is expressed at high levels in majority of the patients who don’t respond to current therapies.

Pharma has been targeting MUC1 for years, but they’ve been attacking the wrong epitopes.

MUC1 is a safe, proven clinical target for ADCs

Daiichi's Phase I clinical trial proved it's a target worth pursuing.*

MUC1 is a safe target for ADCs.
No MUC1-related adverse events observed
in any of the patients.
Most AE were low grade and related to
>8mg/kg of DXd payload.
MUC1 is druggable by ADCs.
MUC1 ADC showed normal PK and PD.
No effect of Shed MUC1 observed.
But, targeting the wrong epitope leads to low efficacy.
10 partial responses in 61 patients (16.3%).
Only 1 complete response in 61 patients (1.6%).

Daiichi’s announced in October 2025, the results of Phase I Clinical Trial for DS-3939, their MUC1-targeting Antibody Drug Conjugate (ADC) with a DXd payload.*

While the world was watching Daiichi…

Daiichi DS-3939 — Short, unstable, few contact points

SANA-01 binds to a better, longer and more stable MUC1 epitope than competitors.

The data proves it

Binding

SANA-01 is engineered for the 80% of patients existing therapies aren’t helping.

SANA-01 ADC Clinical Trial starting in Summer 2027

Our proprietary platform can help more patients fight more cancers.

Lower dosage, fewer side effects. Better binding, more efficacy.

SANA-01
DLTEffective Dose
A body with activity at the target site only
A body with off-target activity spreading beyond the target site
Competition
Effective DoseDLT

Tech

This is how a better antibody discovery platform works:

Target Epitope

Traditional Approach

Generate Antibodies

Select by sequence

Tested in the lab

Only a few validated antibodies

Sanavia’s Antibody Discovery Platform

Multidimensional functional dataset

(sequence, structure, specificity, binding, affinity, internalization)

Proprietary ML model selects antibodies based on structure and function instead of just sequence

Tight loop between the wetlab and the cloud improves ML model

Validated in the wetlab

A bigger pool of better options for finding the antibody with the perfect geometry of binding
Traditional Approach
10,000
OptionsValidated candidates
Sanavia's Antibody Discovery Platform
10,000
OptionsValidated candidates
Sanavia's Antibody Discovery Platform
10,000
Options
9,500
Validated candidates
Zero
Guesses

As the cost of discovery drops, 
the quality rises.

Who We Are
SANA-01 ADC
Next Generation Therapies
Pitch Deck for Business Development – Sanavia